SCHEMBL1973105

SCHEMBL1973105

CCCCOC(=O)c1nc(C)c2sc(-c3ccc(Oc4ccccc4)cc3)cc2c1O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.42
EGLN1 Q9GZT9 6/20 0.42
BBOX1 O75936 1/20 0.42
THRA P10827 1/20 0.42
THRB P10828 1/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A3 Q01959 1/20 0.42
ASPH Q12797 1/20 0.42
KDM8 Q8N371 1/20 0.42
FTO Q9C0B1 1/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
EGLN2 Q96KS0 3/20 0.41
P2RX3 P56373 1/20 0.39
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 1/20 0.38
DDX3X O00571 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1976686 0.93 SCN9A (0.42) SCN9AEGLN1BBOX1THRATHRB
SCHEMBL1974153 0.91 POLB (0.42) SCN9AEGLN1BBOX1THRATHRB
SCHEMBL1977214 0.90 EGLN1 (0.41) SCN9AEGLN1BBOX1THRATHRB
SCHEMBL1975813 0.88 POLB (0.42) SCN9AEGLN1POLBMAPTEGLN2
SCHEMBL1974064 0.87 MAPT (0.43) POLBMAPTALDH1A1KDM4EHPGD
SCHEMBL1975055 0.86 EGLN1 (0.41) SCN9AEGLN1THRATHRBPOLB
SCHEMBL1971890 0.85 MAPT (0.47) EGLN1POLBMAPTEGLN2ALDH1A1
SCHEMBL1980025 0.83 EGLN2 (0.45) EGLN1BBOX1THRATHRBSLC6A2
SCHEMBL1975064 0.82 EGLN1 (0.39) SCN9AEGLN1POLBMAPTEGLN2
SCHEMBL1973999 0.82 MAPT (0.42) SCN9AEGLN1POLBMAPTEGLN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9000006-B2 Thienopyridine compounds, and methods of use thereof FIBROGEN, INC. (US) 2015-04-07 US disclosed
US-20140221422-A1 NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. (US) 2014-08-07 US disclosed
US-8703795-B2 Thienopyridine compounds, and methods of use thereof FIBROGEN, INC. (US) 2014-04-22 US disclosed
EP-1866318-B1 THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN INC (US) 2011-06-22 EP disclosed
EP-1866318-A2 THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. (US) 2007-12-19 EP disclosed
WO-2006094292-A2 THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. (US) 2006-09-08 WO disclosed
US-20060199836-A1 Novel thienopyridine compounds, and methods of use thereof FIBROGEN, INC. 2006-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221422-A1 NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN2 SCN9A 2842/4885EGLN1 7/4885BBOX1 502/4885
US-20060199836-A1 Novel thienopyridine compounds, and methods of use thereof HIF1AN, HIF1A, EGLN2 SCN9A 2842/4885EGLN1 7/4885BBOX1 502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.